3.6. uncomplicated pyelonephritis. uncomplicated pyelonephritis defined pyelonephritis limited non-pregnant, pre-menopausal women known relevant urological abnormalities comorbidities. 3.6.1. diagnostic evaluation 3.6.1.1. clinical diagnosis pyelonephritis suggested fever (> 38Â°c), chills, flank pain, nausea, vomiting, costovertebral angle tenderness, without typical symptoms cystitis . pregnant women acute pyelonephritis need special attention, kind infection may adverse effect mother anaemia, renal respiratory insufficiency, also unborn child frequent pre-term labour birth . 3.6.1.2. differential diagnosis vital differentiate soon possible uncomplicated complicated mostly obstructive pyelonephritis, latter rapidly lead urosepsis. differential diagnosis made appropriate imaging technique (see section 3.6.1.4). 3.6.1.3. laboratory diagnosis urinalysis including assessment white red blood cells nitrite, recommended routine diagnosis . addition, urine culture antimicrobial susceptibility testing performed cases pyelonephritis. 3.6.1.4. imaging diagnosis evaluation upper urinary tract ultrasound (us) performed rule urinary tract obstruction renal stone disease patients history urolithiasis, renal function disturbances high urine ph . additional investigations, contrast enhanced computed tomography (ct) scan, excretory urography considered patient remains febrile 72 hours treatment, immediately deterioration clinical status . diagnosis complicating factors pregnant women, us magnetic resonance imaging (mri) used preferentially avoid radiation risk foetus . 3.6.2. summary evidence recommendations diagnostic evaluation uncomplicated pyelonephritis summary evidenceleurine culture antimicrobial susceptibility testing performed cases pyelonephritis addition urinalysis.4a prospective observational cohort study found radiologic imaging selectively applied adults febrile uti without loss clinically relevant information using simple clinical prediction rule.2badditional imaging investigations, unenhanced helical computed tomography done patient remains febrile 72 hours treatment patients suspected complications e.g. sepsis.4 recommendationsstrength ratingperform urinalysis (e.g. using dipstick method), including assessment white red blood cells nitrite, routine diagnosis.strongperform urine culture antimicrobial susceptibility testing patients pyelonephritis.strongperform imaging urinary tract exclude urgent urological disorders.strong 3.6.3. disease management 3.6.3.1. outpatient treatment fluoroquinolones cephalosporines antimicrobial agents recommended oral empirical treatment uncomplicated pyelonephritis . however, oral cephalosporines achieve significantly lower blood urinary concentrations intravenous cephalosporines. agents nitrofurantoin, oral fosfomycin, pivmecillinam avoided insufficient data regarding efficacy . setting fluoroquinolone hypersensitivity known resistance, acceptable choices include trimethoprim-sulfamethoxazole (160/800 mg) oral beta-lactam, uropathogen known susceptible. agents used absence antimicrobial susceptibility results, initial intravenous dose long-acting parenteral antimicrobial (e.g. ceftriaxone) administered. short outpatient antibiotic course treatment, acute pyelonephritis, shown equivalent longer durations therapy terms clinical microbiological success. however, associated higher recurrence rate infection within four six weeks needs tailored local policies resistance patterns . 3.6.3.2. inpatient treatment patients uncomplicated pyelonephritis requiring hospitalisation treated initially intravenous antimicrobial regimen e.g. fluoroquinolone, aminoglycoside (with without ampicillin), extended-spectrum cephalosporin penicillin . ceftolozane/tazobactam achieved clinical response rate 90% patients uncomplicated pyelonephritis . also demonstrated significantly higher composite cure rates levofloxacin among levofloxacin-resistant pathogens . ceftazidime-avibactam combination shown effective treating ceftazidime-resistant enterobacterales pseudomonas aeruginosa utis . novel antimicrobial agents include imipenem/cilastatin, cefiderocol, meropenem-vaborbactam plazomicin. imipenem/cilastatin investigated phase 2 randomised trial showed good clinical response rates . cefatazidime-avibactam doripenem showed similar efficacy ceftazidime non-susceptible pathogens may offer alternative carbapenems setting . meropenem-vaborbactam shown non-inferior piperacillin-tazobactam phase 3 rct . also effective treating carbapenem-resistant enterobacterales cure rates 65% compared best available treatment . daily plazomicin non-inferior meropenem treatment cutis acute pyelonephritis caused enterobacterales, including multidrug-resistant strains . cefiderocol non-inferior imipenem/cilastatin treatment complicated uti people multidrug-resistant gram-negative infections phase 2 rct . carbapenems novel broad spectrum antimicrobial agents considered patients early culture results indicating presence multi-drug resistant organisms. choice agents based local resistance patterns optimised basis drug susceptibility results. patients presenting signs urosepsis empiric antimicrobial coverage esbl-producing organisms warranted . patients initially treated parenteral therapy improve clinically tolerate oral fluids may transition oral antimicrobial therapy . 3.6.3.2.1. summary evidence recommendations treatment uncomplicated pyelonephritis summary evidencelefluoroquinolones cephalosporines microbial agents recommended oral empirical treatment uncomplicated pyelonephritis.1bintravenous antimicrobial regimens uncomplicated pyelonephritis may include fluoroquinolone, aminoglycoside (with without ampicillin), extended-spectrum cephalosporin penicillin.1bcarbapenems considered patients early culture results indicating presence multi-drug resistant organisms.4the appropriate antimicrobial chosen based local resistance patterns optimised basis drug susceptibility results.3 recommendationsstrength ratingtreat patients uncomplicated pyelonephritis requiring hospitalisation short course fluoroquinolones first-line treatment.strongtreat patients uncomplicated pyelonephritis requiring hospitalisation intravenous antimicrobial regimen initially.strongswitch patients initially treated parenteral therapy, improve clinically tolerate oral fluids, oral antimicrobial therapy.strongdo use nitrofurantoin, oral fosfomycin, pivmecillinam treat uncomplicated pyelonephritis.strong table 3: suggested regimens empirical oral antimicrobial therapy uncomplicated pyelonephritis antimicrobialdaily doseduration therapycommentsciprofloxacin500-750 mg b.i.d7 daysfluoroquinolone resistance less 10%.levofloxacin750 mg q.d5 daystrimethoprim sulfamethoxazol160/800 mg b.i.d14 daysif agents used empirically, initial intravenous dose long-acting parenteral antimicrobial (e.g. ceftriaxone) administered.cefpodoxime200 mg b.i.d10 daysceftibuten400 mg q.d10 days b.i.d = twice daily; q.d = every day. table 4: suggested regimens empirical parenteral antimicrobial therapy uncomplicated pyelonephritis antimicrobialsdaily dosecommentsfirst-line treatmentciprofloxacin400 mg b.i.dlevofloxacin750 mg q.dcefotaxime2 g t.i.dnot studied monotherapy acute uncomplicated pyelonephritis.ceftriaxone1-2 g q.dlower dose studied, higher dose recommended.second-line treatmentcefepime1-2 g b.i.dlower dose studied, higher dose recommended.piperacillin/tazobactam2.5-4.5 g t.i.dgentamicin5 mg/kg q.dnot studied monotherapy acute uncomplicated pyelonephritis.amikacin15 mg/kg q.dlast-line alternativesimipenem/cilastatin0.5 g t.i.dconsider patients early culture results indicating presence multi-drug resistant organisms.meropenem1 g t.i.dceftolozane/tazobactam1.5 g t.i.dceftazidime/avibactam2.5 g t.i.dcefiderocol2g t.i.dmeropenem-vaborbactam2g t.i.dplazomicin15mg/kg o.d b.i.d = twice daily; t.i.d = three times daily; q.d = every day; o.d = daily. pregnant women pyelonephritis, outpatient management appropriate parenteral antimicrobials may also considered, provided symptoms mild close follow-up feasible . severe cases pyelonephritis, hospitalisation supportive care usually required. clinical improvement parenteral therapy also switched oral therapy total treatment duration seven ten days. men febrile uti, pyelonephritis, recurrent infection, whenever complicating factor suspected minimum treatment duration two weeks recommended, preferably fluoroquinolone since prostatic involvement frequent . 3.6.4. follow-up post-treatment urinalysis urine cultures asymptomatic patients post-therapy indicated.